Two patients with high-risk acute myeloid leukemia (AML) whose bone marrow aspirates showed more than 25% blasts between 2 and 4 weeks after the first induction chemotherapy immediately received modified conditioning therapy with intravenous busulfan at 50% of the usual dose and fludarabine, before hematologic recovery occurred. Unmanipulated G-CSF mobilized peripheral blood stem cells from an HLA-identical sibling donor were transfused and haematopoietic recovery was achieved in both recipients. Both of them are in continuing hematological remission with full donor chimerism 12 and 22 months after transplantation. Early treatment intensification with allogeneic cell therapy during marrow aplasia might cure high-risk AML patients who are unlikely to achieve remission with conventional chemotherapy protocols. Bone Marrow Transplantation (2001) 27, 543-546.
Patients with acute myeloid leukemia who do not achieve remission after induction chemotherapy have a poor prognosis, especially when additional cytogenetic risk factors are present. 1 Although allogeneic bone marrow transplantation is considered to be the treatment of choice for most high-risk patients, refractory leukemia is the main reason why those patients will not undergo transplantation 2, 3 since even allogeneic bone marrow transplantation will rarely induce remission in patients with a high leukemia burden. 4 To address this problem, we studied the feasibility of early allogeneic blood stem cell transplantation in patients whose bone marrow showed insufficient reduction in the percentage of blasts after the first cycle of induction chemotherapy. To reduce the toxicity associated with intensive conditioning shortly after primary chemotherapy, we used a regimen 
Materials and methods
The chemotherapy and transplantation protocol are part of the multicenter AML SHG 96 trial of the 'Süddeutsche Hämoblastosegruppe' and had been approved by the local ethical board. Induction chemotherapy (MAV) included cytosine arabinoside at a daily dose of 100 mg/m 2 as a continuous infusion for 8 days, mitoxantrone 10 mg/m 2 and etoposide 100 mg/m 2 per day for 5 days. Bone marrow aspiration was performed in every patient 2 weeks after the start of chemotherapy and whenever hematologic recovery appeared delayed. HLA-typing was done serologically for class I antigens and with DNA typing for HLA DRB1 and DQB1. Peripheral blood stem cells (PBSC) from donors were mobilized with granulocyte colony-stimulating factor (G-CSF) at a daily dose of 7.5 g/kg subcutaneously for 5 days. One large volume leukapheresis was performed on the 5th day.
The modified conditioning therapy contained busulfan 3.3 mg/kg i.v. for 2 days and fludarabine 30 mg/m 2 i.v. daily for 5 days. Previous studies in humans had shown 3.3 mg/kg i.v. to be equivalent to 4 mg/kg busulfan given orally in a single dose (data not shown). Both PBSC grafts were infused without further manipulation. Cyclosporin A (CsA) 5 mg/kg i.v. was given as graft-versus-host disease (GVHD) prophylaxis. Both patients received oral ciprofloxacin, fluconazole and acyclovir as antimicrobial prophylaxis until day +100 after transplantation.
Quantitative chimerism analysis was performed with a commercial polymerase chain (PCR) reaction assay for nine short-tandem repeat (STR) markers out of peripheral blood and bone marrow specimens, as described before.
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Results
Case 1
A 44-year-old male was diagnosed AML, FAB M0 with 38% bone marrow myeloblasts in October 1998 after a documented MDS phase of 6 months. Cytogenetic analysis revealed translocation t(3;3) with additional trisomy 22. No significant extramedullary toxicity was observed during the first cycle of induction chemotherapy (Figure 1a and b). Hematologic recovery was delayed and bone marrow aspiration performed 4 weeks after induction chemotherapy revealed a hypocellular marrow with 34% atypical blasts still present. Early typing had shown the patient's brother to be HLA-identical. Conditioning therapy was started 1 week later when the patient was still aplastic. A PBSC graft containing 7.45 × 10 6 CD34 positive cells/kg was infused after conditioning. The patient subsequently suffered from mucositis WHO grade 2 and liver transaminases elevated four-fold above baseline, and returned to normal levels without specific therapy. Engraftment with more than 0.5 × 10 9 neutrophils/l and more than 50 × 10 9 platelets/l occurred on day 11 and 12 post-transplant, respectively. Only one platelet and two red blood cell transfusions were required during that time period. The patient left the hospital 3 weeks after transplant. On day 80, GVHD of the gut was diagnosed by endoscopy and ileal biopsy. Treatment with 2 mg/kg prednisolone was started and he required admission to the hospital for 3 further weeks. Although diarrhea resolved gradually, the patient still suffers from malabsorption and reduced body weight. Quantitative chimerism analysis using PCR for the informative shorttandem repeat markers has shown complete donor chimerism for 22 months. A bone marrow aspiration 9 months after transplantation documented complete cytological remission. The peripheral blood counts have since remained stable.
Case 2
After a phase of pancytopenia, a 40-year-old female was diagnosed with AML, FAB M4 with 58% atypical bone marrow blasts in August 1999. Cytogenetics revealed a duplication of chromosome 2. Bone marrow aspiration showed a hypocellular smear with 63% blasts 2 weeks after MAV induction chemotherapy. The patient's sister had been identified as HLA-identical and 2.4 × 10 6 CD34 positive PBSC/kg were infused after conditioning therapy with busulfan and fludarabine during persistent aplasia (Figure 1c and d) . Only mild mucositis occurred with no need for analgesics. Hematologic recovery was rapid and transfusion requirements low. Acute GVHD grade II of the skin was diagnosed on day +9 and was treated with 2 mg/kg prednisolone i.v. which was tapered rapidly. Cytological examination on day +100 confirmed hematological remission. Cytogenetic analysis revealed a normal female karyotype. Molecular analysis showed complete donor chimerism in bone marrow cells and peripheral blood leukocytes. The patient is alive 12 months after transplantation with a Karnofsky score of 80%.
Discussion
Patients with AML who do not respond to induction chemotherapy have a poor prognosis and although they might benefit from an allogeneic stem cell transplant, early disease progression and death during salvage treatment invariably prevent transplantation. 2 Although salvage chemotherapy and subsequent allogeneic BMT with a high procedure-related toxicity are one possible strategy for younger patients with refractory or relapsing disease, 6,7 the ultimate goal would be to identify non-responders earlier and perform the allogeneic transplant immediately, thereby sparing some toxicity.
Allogeneic transplantation after dose reduced or nonmyeloablative conditioning has been pioneered by several groups over the last few years with the aim of offering a potentially curative treatment to older patients with a reduced performance status. Most of these conditioning regimens include purine analogues combined with alkylating agents in reduced doses. 7, 8 Only recently have low-dose total body irradiation with 200 cGy, CsA and mycophenolate mofetil been shown to allow allogeneic lymphohematopoietic engraftment. 9 The same authors have treated a patient with marrow aplasia and pulmonary aspergillosis with this type of immunosuppressive conditioning. 10 We have now used a fludarabine-based conditioning regimen in AML patients early during marrow aplasia not because of fungal infection or older age of the recipient but to induce durable remission when no decrease in blast counts is achieved after initial induction chemotherapy. The extramedullary toxicity of the conditioning therapy was moderate even when started during marrow aplasia only 2 to 4 weeks after the previous chemotherapy cycle. Intravenous busulfan is advantageous in patients who might already suffer from stomatitis and those who have problems with swallowing capsules. The dose infused in our study corresponds to 50% of the usual dose given orally and was sufficient to eliminate a limited amount of leukemic burden shortly after induction chemotherapy. Hematopoietic recovery was fast in both patients preventing them from developing infectious complications. More patients will have to be studied to make a final conclusion concerning the cumulative toxicity of our approach. Given the low incidence of early toxicity seen in 24 patients with varying diseases and reduced performance status receiving the same conditioning regimen and blood stem cell transplantation from matched sibling donors as consolidation therapy, 11 this might also hold true for AML patients treated as early as described here.
The patient cohort which should benefit from early allogeneic blood stem cell transplantation still needs to be defined. Currently, we suggest that younger patients with high risk cytogenetic aberrations and secondary AML could Bone Marrow Transplantation be included in prospective studies evaluating the possibility of remission induction with allogeneic stem cell transplantation. Insufficient clearance of blasts, defined in our study as more than 25% blasts 1 week after the end of the first induction chemotherapy, is another possible inclusion criterion which could identify patients with a decreased duration of relapse-free survival. Nevertheless, overall toxicity of this approach might limit the inclusion of patients beyond the age of 65. HLA typing of possible donors as well as donor examination should certainly be performed as fast as possible after the patient is diagnosed with highrisk AML. If no sibling donor is available at short notice, the search for a matched unrelated donor might be an alternative strategy, which should also be studied in prospective trials.
One could speculate, that an allogeneic graft-versus-leukemia effect may succeed in inducing stable remission with a limited stage of residual disease before secondary drug resistance has become a major problem. In addition, the cumulative toxicity of this approach is limited in comparison to most standard AML protocols incorporating induction and intensive postremission therapy or allogeneic bone marrow transplantation.
12 Whether the relapse-free survival of high-risk patients can be prolonged with this or similar strategies will be investigated in a prospective manner.
